||Proposed Legislation for One-Year SGR Patch Would Also Change ESRD Regulations, Delay ICD-10; Swift Passage Likely
121-page pdf from
House.gov. Articles from HFMA, The Hill's HealthWatch blog, Bloomberg, and Government Health IT.
212, page 19 (based on numbers on top of pages) would delay the transition from ICD-9 to ICD-10 for one year.
217, pages 58-62 (based on numbers on top of pages) would modify several Medicare ESRD provisions. Most notably, it would change the date of the inclusion of oral drugs into the bundle from 2016 to 2024.
Quote from AP article:
"It also contains a provision benefiting, among others, Amgen Inc., which produces an oral drug for kidney dialysis patients. It would extend through 2024 a controversial provision to allow payments for Sensipar, which is made by Amgen, to be made on top of other "bundled" payments made to treat Medicare patients with kidney disease. It also eases cuts to dialysis providers who have battled with drug companies over the issue."
Quote from Modern Healthcare article:
"Both leaders have pledged to allow an up or down vote, Nachimson said, with the House going first on Thursday and the Senate Friday. “This thing, I think, came up rather quickly. It caught a few people by surprise, including me.”
Editor's note: It appears that Amgen is once again inserting provisions into last-minute legislation — little discussed or debated — which greatly enrich Amgen. Amgen knows that payment drives practice in ESRD care... patients be damned.